Current Trastuzumab News and Events | Page 7

Current Trastuzumab News and Events, Trastuzumab News Articles.
Sort By: Most Relevant | Most Viewed
Page 7 of 7 | 261 Results
Herceptin treatment lowers recurrence rate in early breast cancer
The targeted drug trastuzumab, or Herceptin, previously shown to prolong survival in advanced breast cancer, dramatically reduced the chances of recurrence in patients with early-stage disease when given for one year following standard chemotherapy. (2005-10-19)

Mayo Clinic reports breakthrough treatment for breast cancer
In a joint paper, co-authored by Mayo Clinic's Edith Perez, M.D., and Edward Romond, M.D., of the National Surgical Adjuvant Breast and Bowel Project (NSABP), researchers report complete and combined results of two trials comparing adjuvant chemotherapy with or without concurrent trastuzumab treatment in women with surgically removed HER2-positive breast cancer. (2005-10-19)

New Herceptin results confirm impressive reduction in risk of cancer returning
Roche announced today that a fourth large phase III trial in early-stage HER2-positive breast cancer has shown that adding Herceptin to chemotherapy significantly reduces the risk of cancer coming back compared to chemotherapy alone. This study follows three earlier phase III studies which also confirmed Herceptin's superiority to chemotherapy alone in early-stage breast cancer. HER2-positive breast cancer is a particularly aggressive form of the disease which affects approximately 20 - 30% of women with breast cancer. (2005-09-14)

Michael R. Zalutsky named recipient of Society of Nuclear Medicine's 2005 Berson-Yalow Award
Michael R. Zalutsky, Ph.D., a professor of radiology and biomedical engineering at Duke University, Durham, N.C., is the recipient of the 2005 Society of Nuclear Medicine's Berson-Yalow Award. This honor is given to the investigator who has submitted the most original scientific abstracts and made the most significant contributions to basic or clinical radioassay. SNM President Mathew Thakur, Ph.D., presented the award on June 21 at the society's 52nd Annual Meeting in Toronto. (2005-06-21)

Mayo researchers to announce new findings about promising early-stage breast cancer treatment
During a poster discussion session at the 2005 American Society of Clinical Onscology (ASCO) Annual Meeting on Tuesday, May 17, Dr. Perez will discuss new information about the potential risk for heart muscle damage associated with the use of trastuzumab and chemotherapy. (2005-05-17)

Mayo researchers to announce new findings about promising early-stage breast cancer treatment
A study led by a Mayo Clinic medical oncologist and conducted by the North Central Cancer Treatment Group (NCCTG) provides important new data about the effectiveness and safety of a breast cancer treatment combining chemotherapy and a drug called trastuzumab (Herceptin). (2005-05-16)

Romond heads up study and reduces breast cancer recurrence
Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin®) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. Dr. Edward Romond, associate professor of medicine at the University of Kentucky College of Medicine and UK Markey Cancer Center, acts as principal investigator on the study and chairs the National Surgical Adjuvant Breast and Bowel Project (NSABP). (2005-04-26)

US researchers uncover the science behind the breast cancer protective effect of olive oil
US researchers have uncovered reasons why the Mediterranean diet, with its high intake of oleic acid-rich olive oil, seems to protect against breast cancer. They have also found evidence that oleic acid may have a future role in treatment. The findings are reported (Monday 10 January) in Annals of Oncology. (2005-01-09)

Powerful predictor of resistance may change management of therapy for breast cancer
Scientists have identified a new mechanism of action for the anticancer drug Herceptin (trastuzumab) that can be used to accurately predict whether or not a breast cancer patient will be resistant to treatment. The finding has dual significance, as it will allow patients who are unlikely to respond to trastuzumab to avoid unnecessary costs and side effects associated with treatment, and it provides new directions for designing strategies for overcoming treatment resistance. (2004-08-23)

New breast cancer drug shrinks tumors or slows growth in up to half of women
A new and experimental breast cancer drug called lapatinib inhibited tumor growth in nearly half of women who took it for eight weeks in a national Phase I clinical trial, according to results of a study being presented at the annual American Society of Clinical Oncology meeting in New Orleans. (2004-06-06)

Other highlights in the May 19 JNCI
Other highlights in the May 19 JNCI include two studies that look for a safe three agent combination therapy for HER2-positive advanced breast cancer, an examination of multiple sclerosis and Hodgkin lymphoma patterns in families, a study of melanoma risks in families without a history of melanoma, and a study that provides clues to the anticancer abilities of vitamin E. (2004-05-18)

Herceptin gives disappointing results in lung cancer trial
Trastuzumab (Herceptin) - a treatment that has increased survival in many breast cancer patients - has failed to live up to hopes that it might also help lung cancer patients reports in the Annals of Oncology. (2004-01-12)

Study finds potential way to improve cancer immunotherapy
Drugs that contain antibodies are a standard part of therapy for many cancers, but these antibodies do not always work. A finding by researchers with the Holden Comprehensive Cancer Center at the UI may help make the antibodies more effective by boosting the power of white blood cells, which play a role in fighting cancer. (2003-09-04)

Studies call for quality assurance in selecting candidates for herceptin trials
Two new studies suggest that local laboratories are not as accurate as central testing facilities at identifying women most likely to benefit from Herceptin. As many as 26% of the patients enrolled in one trial of Herceptin may not be the best candidates to determine whether Herceptin is advantageous as an adjuvant therapy for breast cancer. The findings appear in the June 5 issue of the Journal of the National Cancer Institute. (2002-06-04)

Hormone therapy for breast cancer - the treatments of the future
Evidence is accumulating that although chemotherapy and hormonal drugs are both effective for patients with early breast cancer, the greater gains are being found from hormone therapy. (2002-03-20)

Reining in cancer
A team of Italian researchers has demonstrated in the laboratory for the first time that combining two of the newest anti-cancer targeted agents may produce a powerful new combination against breast cancer - and possibly many other cancers as well. (2002-01-23)

Results from second phase II trial suggest synergistic effects of navelbine in combination with herceptin for Her2 positive metastatic breast cancer
Researchers investigating the combination of Navelbine® (vinorelbine tartrate) Injection, a first-line chemotherapy treatment for advanced non-small cell lung cancer, and the monoclonal antibody therapy Herceptin® (trastuzumab), reported an overall response rate of 78 percent in women with HER2 positive metastatic breast cancer, in presenting results of a Phase II study at the 24th Annual San Antonio Breast Cancer Symposium. Navelbine is not indicated for use in women with metastatic breast cancer. (2001-12-12)

HERA (HERceptin Adjuvant) trial recruitment begins
The HERA (HERceptin Adjuvant) trial recruitment begins - one of the largest ever breast cancer studies to look at the benefits of Herceptin (trastuzumab) in Adjuvant Breast Cancer. Enrolment will begin in November from over 600 trial sites across the world and it is hoped that more than 3000 patients will be recruited. (2001-10-24)

Preclinical data of Introgen's INGN 241 demonstrate broad anti-cancer activity in multiple tumor types as monotherapy and in combination
Introgen reports preclinical findings demonstrating that INGN 241, an Adenoviral vector encoding the mda-7 gene can inhibit cell growth in multiple tumor types when used alone or in combination with established therapies. These data were presented as three separate studies at the Meeting of the American Society for Gene Therapy. (2001-06-01)

Report in Circulation urges a closer look at cardiotoxicity of cancer drug trastuzumab (Herceptin)
According to a report by a University of Pittsburgh cardiologist published in the current edition of (2000-07-17)

UCSD-Salk Institute awards presented to Christopher Reeve, Dr. Donald Seldin, Genentech, Inc. and Dr. Dennis Slamon
The first UCSD-Salk Institute Service Award was presented to Christopher Reeve. The international symposium, (2000-03-20)

Page 7 of 7 | 261 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to